Targeted therapy and hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in pediatric and adolescent patients: a pilot protocol results
Background. Introduction a targeted drugs in a real clinical practice bring a vast improvement of prognosis in patients with relapsed and refractory (r/r) Hodgkin lymphoma (HL). But it is necessary to increase the experience in anti-CD30 monoclonal antibodies in combination with second-line chemothe...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2023-05-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/viewFile/271831/pdf |
| Summary: | Background. Introduction a targeted drugs in a real clinical practice bring a vast improvement of prognosis in patients with relapsed and refractory (r/r) Hodgkin lymphoma (HL). But it is necessary to increase the experience in anti-CD30 monoclonal antibodies in combination with second-line chemotherapy in pediatric oncology/hematology.
Aim. To estimate the effectiveness of chemoimmunotherapy (ViGePD+BV scheme) in pediatric patients with r/r classical HL (cHL).
Materials and methods. From January 2018 to October 2022, 15 patients with r/r cHL received scheme ViGePD+BV. Programmed treatment included autologous stem cell transplantation (auto-SCT) in 11 (73%) patients. The potency assignment of antitumour treatment was performed with positron emission tomography/computed tomogtaphy (PET-CT).
Results. Complete metabolic response (PET-negative status) was achieved in all 15 (100%) patients after 4 inductive courses by ViGePD+BV scheme; 4-year relapse-free survival was 90.98.7%.
Conclusion. Our preliminary data of a pilot protocol of study a chemoimmunotherapy effectiveness for r/r cHL with brentuximab vedotin show a high potency of ViGePD+BV scheme in patients with r/r HL. |
|---|---|
| ISSN: | 1815-1434 1815-1442 |